GlaxoSmithKline to Buy Wyeth Vaccine Facility

GlaxoSmithKline, Europe’s largest drug maker, agreed to buy a U.S. vaccine production and research facility from Wyeth to increase production capacity of flu immunizations and to develop other treatments.

The terms of the acquisition are confidential, London-based Glaxo said. The Marietta, Pa., site will employ about 270 people.